• Prana Biotechnology Ltd., of Melbourne, Australia, said data from the Phase II Reach 2HD trial testing PBT2 in Huntington’s disease would be reported in early 2014 rather than the fourth quarter of this year, due to a delay in finalizing the database and locking the data prior to statistical analysis.